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Introduction
Staphylococcus aureus bacteraemia (SAB) is an often underestimated and common disease [1, 2] with reported annual incidence rates of 10e32 cases/100 000 inhabitants [3] . If treated insufficiently, mortality rates can reach up to 50% and recurrences are frequent [1, 4] . Outcomes of SAB can be improved with routine infectious disease consultations that enhance adherence to treatment guidelines, including choice of appropriate antibiotic agent [5] . Treatment of patients with methicillin-sensitive S. aureus (MSSA) bacteraemia relies on the intravenous administration of antibiotics with high anti-staphylococcal activity. Antistaphylococcal penicillins (ASP) such as flucloxacillin, naficillin or cloxacillin are considered first-line agents for the treatment of bacteraemia caused by MSSA strains [6] .
Whether the first-generation cephalosporin cefazolin is as effective as ASPs is an ongoing matter of debate [7e9] . Based on in vitro studies, it is considered vulnerable to the so-called 'inoculum effect' describing an increase in the minimum inhibitory concentration (MIC) in the presence of a large number of bacteria as expected particularly in endocarditis, osteomyelitis, septic arthritis, pneumonia and large abscesses [10, 11] . This inoculum effect is mostly observed with specific strains of MSSA, which produce a type A beta-lactamase. The prevalence of MSSA strains exhibiting a cefazolin inoculum effect varies depending on the geographic region and ranges from 19 to 27% in the USA [12, 13] , from 26 to 46% in South America [14] , from 13 to 58% in South Korea [12, 15] and is only 6% in Japan [16] . The clinical implications of this in vitro phenomenon on the treatment of MSSA infections, however, are unclear [13] . In addition, due to its broader bacterial spectrum, there is concern that complications such as Clostridium difficile enteritis or the selection of multi-resistant bacteria may be more likely to occur with cefazolin than with ASPs [17] . Conversely, cefazolin has a longer half-life and thus is more convenient to dose compared to nafcillin or oxacillin and appears to be less nephroand hepatotoxic than ASPs [6] .
We aimed to perform a systematic literature review and metaanalysis to assess current available clinical evidence comparing cefazolin with anti-staphylococcal penicillins for patients with SAB. Furthermore, we were interested in whether the outcome of patients with a potentially higher pathogen load, i.e. patients with endocarditis or abscesses, had a worse outcome when treated with cefazolin as compared with ASPs.
Materials and methods

Elegibility criteria
All studies investigating the effects of cefazolin versus ASP in patients with methicillin-sensitive SAB were eligible for inclusion regardless of study design, publication status or language. There was no minimal number of patients. The primary endpoint was 90-day all-cause mortality. Secondary endpoints included 30-day allcause mortality, treatment failure/relapse and nephrotoxicity. Given the varying description for relapse and that some studies reported on the endpoint treatment failure, while both indicating insufficient treatment, both outcomes were reported together as one. Definitions are provided in Supplementary Table S1 . Other toxicities such as hepatitis, phlebitis or cytopenia were not routinely reported and therefore not assessed. In-hospital mortality as reported by some studies was explicitly not assessed as it was considered as less informative given it is known to substantially vary between countries. Studies that reported on this outcome only were not considered.
Information sources and search
MEDLINE, ISI Web of Science (Science Citation Index Expanded) and the Cochrane Database as well as clinicaltrials.gov were searched from inception to 26 June 2018 for clinical studies reporting outcomes of SAB patients treated with cefazolin or ASPs. The search terms are provided in Supplementary Table S2 . Database searches were complemented by screening the reference lists of relevant studies and reviews as well as by directly asking selected experts for studies that they were aware of, but which were not already included in this analysis. Two authors (S.W., S.H.) independently performed the literature search, identified all studies potentially relevant for this review and selected studies that were included. Conflicts over inclusion were resolved through consensus. All study authors were contacted in order to retrieve all additional available data (also concerning missing data).
Data collection process and risk of bias assessment
One author (S.W.) extracted the number of patients and events for both treatment groups (cefazolin or ASP). Results were independently validated by one other author (S.H.). To assess potential heterogeneity of the study populations, we extracted information on study designs and settings as well as summarized patient characteristics. A formal risk assessment of the individual studies was judged independently by two authors (S.W. and S.H.) according to the NewcastleeOttawa Scale (NOS) (Supplementary Table S3 ) [18] . Differences between the judgements were resolved by discussion. The certainty of evidence was assessed using the guidelines of the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working group [19, 20] .
Synthesis of results
In random-effects meta-analyses, we pooled relative risks (RRs) with 95% confidence intervals (CIs). Studies were pooled according to the ManteleHaenszel and DerSimonianeLaird methods for within-study and between-study variance, respectively [21e23]. In studies with zero cell frequencies, a continuity correction of 0.5 was used. Statistical heterogeneity was assessed by I 2 statistic. Heterogeneity was judged to be low for I 2 0e40%, moderate for I 2 30e60%, to be substantial for I 2 50e90% and to be considerable for I 2 75e100%. The importance of this measure depends on the magnitude and direction of effects as well as the precision of the estimate (often judged by the corresponding pvalue from the Chi-squared test) [24] . Meta-analysis results are presented as forest plots. In addition, funnel plots were inspected to identify potential evidence for publication bias. To assess a possible indication bias in this context, we performed randomeffects meta-analyses to compare the proportions of patients with endocarditis and abscesses in the two treatment groups across all studies reporting these data. In sensitivity analyses of the complete data sets, we also calculated the meta-analysis odds ratio (OR), and performed a leave-one-out cross-validation. We report point estimates and the corresponding 95% CIs. All analyses were performed with R (version 3.4.3 and 3.5.1; R package meta, version 4.9-0) [25, 26] . Subgroup analysis was performed for patients with endocarditis or abscesses which are suggested to be associated with high pathogen load. Two additional subgroups were performed. The first comprised studies comparing cefazolin to nafcillin treatment as this ASP was used in the majority of studies. The second was restricted to studies applying propensity score matching, i.e. matched patients according to their propensity score. This did not include studies with propensity score adjustment in their analyses. In case, subgroups or respective outcome parameters were not reported in the primary publication, authors of the included studies were asked to provide additional information. 
Results
Our database search revealed 385 reports. One study was in press but did not appear on the literature search [27] (Table 1 , Fig. 1 ). A total of 69 duplicates were removed. From the remaining 317 references, 303 studies were excluded due to lack of relevant information regarding our predefined outcome parameters. Finally, we identified and analysed 14 studies that had investigated at least one of the outcome parameters. All studies were cohort studies. None of the studies was randomized. All but one study relied on a retrospective data collection [9] . The majority of the studies were conducted in the USA (n ¼ 8) and were single centre (n ¼ 8). Among the included studies, the ASP of choice was nafcillin in six studies, cloxacillin in three studies, oxacillin in three studies, flucloxacillin in one study and both nafcillin and cloxacillin in one study. Detailed characteristics of the included studies are provided in Table 1 . Additional information was provided by the authors of five studies [8,9,28e30] . Two studies reported SAB-associated mortality and were analyzed together with the respective outcome analyses [29, 30] . SAB-associated mortality was not specifically defined in the respective studies. There was no difference in the proportion of patients with abscesses in all studies (RR of 0.92 (0.64, 1.33)). The proportion of patients with endocarditis in all studies was lower in the cefazolin than in the ASP treatment group (RR of 0.68 (0.55, 0.85), Supplementary Fig. S1 ).
Assessment of bias within studies
The quality of the individual studies was assessed using the NOS score [18] (Supplementary Table 3) . None of the studies reached the maximum score of nine. Regarding the criterion 'Selection', all but three studies obtained 4/4 points [31e33]. Regarding the criterion 'Comparability', only two studies received 2/2 stars [9, 29] as they had performed propensity score matching. Three studies received no stars due to relevant imbalances of the cohorts [32e34]. Regarding the criterion 'Outcome', none of the studies received 3/3 stars mostly because the adequacy of the follow-up of cohorts was judged to be insufficient, as patients lost to follow-up were not reported.
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Data for meta-analysis only in a subgroup that could not be extracted Fig. 1 . PRISMA flow diagram of study identification and selection process for outcome analysis 431 (modified from Moher and colleagues) [42] . We are very confident that the true effect lies close to that of the estimate of the effect. Further research is very unlikely to change our confidence in the estimate of effect. MODERATE: We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. LOW: Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. VERY LOW: We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. Each issue judged as bearing of serious meaning resulted in the assessed features were had a serious risk quality of evidence was downgraded by one. 1 Inconsistency (heterogeneity) was judged to be not serious when heterogeneity was low or moderate. 2 Judged as serious due to the imprecise and inconsistent definitions among studies. 3 Quality of evidence was up-graded due to the strong and consistent observed effect.
Primary endpoint: 90-day all-cause mortality
For the primary endpoint 90-day all-cause mortality, data from seven studies comprising 4391 patients were extracted ( Fig. 2(a) ). Pooling these results, we observed an overall 90-day mortality of 25.1% (703/2,802) in the ASP group and 18.2% (289/1,589) in the cefazolin group, resulting in an RR of 0.71, 95% CI (0.50, 1.02)). There was moderate heterogeneity in the studies reporting the primary endpoint (I 2 ¼ 63%, p ¼ 0.01). Cefazolin may therefore not be associated with increased 90-day mortality (low-quality evidence).
Secondary endpoints
For the secondary endpoints, we identified 10 studies reporting 30-day all-cause mortality with 11 760 patients (Fig. 2(b) ), 10 studies reporting on treatment failure/relapse (4609 patients; Fig. 2(c) ) and six studies reporting on nephrotoxicity (1188 patients; Fig. 2(d) ). Pooling these studies, cefazolin treatment may be associated with lower 30-day mortality rates (low-quality evidence, RR 0.70 (0.54, 0.91)) and less nephrotoxicity (low-quality evidence, RR 0.36 (0.21, 0.59)). We are uncertain whether cefazolin and ASP differ regarding treatment failure/relapse as the quality of the evidence has been assessed as very low, RR of 0.84 (0.59, 1.18) Table S2 ).
Assessment of bias across studies
Funnel plots revealed no evidence of publication bias, particularly for those studies reporting 30-day all-cause mortality ( Supplementary Fig. S2) . However, the small number of considered studies hampered the assessment. According to the GRADE classification, we judged the certainty of evidence to be low mainly due to the inherent high risk of bias introduced by retrospective, nonrandomized trial designs (Table 2 ). In particular, an indication bias could not be ruled out, which could possibly overestimate the favourable treatment effect of cefazolin compared to ASPs.
Sensitivity and subgroup analyses
The results of the sensitivity analyses supported the main conclusions. Considering the different effect measures (RR versus OR), the results were relatively robust (Supplementary Table S4 ). In the leave-one-out cross-validation, we observed that the direction of the pooled point estimates was relatively robust (Supplementary  Table S5 ).
For the subgroup analysis of infections with potential high pathogen inoculum, we identified three studies reporting on 90-day all-cause mortality (42 patients with endocarditis, Fig. 3 Fig. 3 . Results of the assessment of the impact of a potential inoculum effect in patients with Staphylococcus aureus bacteraemia with endocarditis. ASP, anti-staphylococcal penicillins; CI, confidence interval; RR, relative risk.
46 patients with abscesses, Fig. 4(a) ) and six studies reporting on 30-day all-cause mortality (652 patients with endocarditis, Fig. 3(b) ; 273 patients with abscesses, Fig. 4(b) ). In the subgroup analyses only comprising studies comparing cefazolin and nafcillin, we identified five studies reporting on the primary outcome (1425 patients with cefazolin; 2519 patients with nafcillin; Supplementary Fig. S3 ). The RR for 90-day all-cause mortality was 0.70 (0.43, 1.14), for 30-day all-cause mortality 0.63 (0.52, 0.77), for treatment failure/relapse 0.89 (0.61, 1.29) and for nephrotoxicity 0.37 (0.20, 0.67) (Supplementary Fig. S3 ). There were only two studies applying propensity score matching that reported crude numbers and both studies were conducted by the same study group [8, 29] . We did not perform a specific analysis for this subset.
Discussion
With this systematic review, we aimed to summarize the current evidence for the choice of cefazolin vs. ASP for patients with methicillin-sensitive SAB. Our literature search identified only nonrandomized cohort studies with inherent high risk of bias. Metaanalysis of the available data demonstrates that treatment with cefazolin was not associated with increased 90-day mortality and associated with a better outcome with regard to the chosen secondary outcomes (i.e. 30-day mortality and nephrotoxicity) as compared to treatment with ASP. A subgroup analysis with patients with potentially high pathogen load, i.e. endocarditis and abscesses, was inconclusive as only two studies reported on these outcome parameters.
The main limitation of our systematic review was that all available evidence was derived from non-randomized, largely single-centre studies with an inherent high risk of bias. In particular, an attrition bias could potentially lead to an underestimation of the cefazolin inoculum effect. The clinical studies were not designed to assess the subgroups of patients with presumed high bacterial load, specifically there were no studies focusing on patients with endocarditis or abscesses. In addition, our search strategy did not specifically include manual searches for unpublished studies other than conference proceedings that are covered by the utilized electronic databases. However, we asked contacted authors whether they were aware of any unpublished or ongoing studies. Our analysis that includes data from over 11 000 patients reveals a relative consistency of the direction of the studies, i. favour cefazolin treatment. To compensate for the heterogeneity of included studies, we performed random-effects meta-analyses and several sensitivity analyses which supported our main conclusions. Of note, rates of endocarditis (cefazolin: 151/2523, 6%, ASP: 780/ 9337, 8.3%) were different between the groups of patients treated with cefazolin vs. ASP considering all studies. Given the observational nature of the studies, it more likely reflects the treating physician choice of treatment contributing to a potential indication bias. A further limitation was that two studies reporting only SABassociated mortality rates were nevertheless included in our metaanalysis as the risk of bias and the inter-study variation was already high and we did not want to ignore two valuable studies. This systematic review provides evidence that cefazolin treatment is associated with decreased rates of nephrotoxicity as compared with ASP. An indication bias e i.e. that sicker patients with increased risk of renal failure were treated with ASPs, as this has been suggested to be the treatment of choice e must be taken into consideration. In this context, age, co-morbidities and polypharmacy, common among the elderly, increase the risk for idiosyncratic drug toxicity of ASP [35, 36] . Of note, three systematic reviews comparing cefazolin vs. ASP have been published in 2018 [37e39]. All three systematic reviews showed an association between lower mortality rates and cefazolin treatment compared with ASP treatment. The main difference and reason why we decided to perform this analysis, nevertheless, is that we identified more studies and more importantly twice as many patients. Also, one main difference to previous systematic reviews is that we performed subgroup analysis on patients with cefazolin vs. nafcillin and with endocarditis and abscesses. Furthermore, our analysis included also non-published additional data, which were requested from and made available by authors from the underlying cohort studies.
Exemplarily, in the most recent systematic review on this topic [39] four studies reported here were not included into the metaanalysis [8, 27, 30, 40] . Also, we are stricter in reporting the outcome parameters. The primary outcome in their study was mortality. Therefore, the authors combined all available mortality data from the included studies in one variable, irrespective of assessed time points (e.g. hospital mortality vs. 30-or 90-day mortality) while we differentiated between the different follow-up periods.
Outweighing the inoculum effect against toxicity
Ranking cefazolin as an alternative agent to ASP only reflects concerns about a possible inactivation of cefazolin at the site of infection with the consequence of therapeutic failures. Most reports of clinical failure with cefazolin are case reports or case series and are limited by a small sample size and possible selection bias [12, 13] . Only Lee et al. recently could demonstrate a higher treatment failure and mortality rate in patients infected with organisms that exhibit a cefazolin inoculum effect [9] . In addition, there is an ongoing debate regarding whether the inoculum effect may be an artefact of current susceptibility testing methods rather than a clinically relevant entity because it likely does not represent true pharmacokinetics and pharmacodynamics exposures seen in clinical settings when repeated dosing regimens are administered [41] . At least in our systematic review, cefazolin treatment was not associated with increased mortality as compared to treatment with ASP in the outcome of patients with potential high pathogen load, i.e. patients with endocarditis or abscesses did not show difference in the outcome whether being treated with cefazolin or ASP. Therefore, clinicians should outweigh the risk of an inoculum effect in patients with potential high pathogen load, for which there is sparse clinical evidence against the clinically well-confirmed risk of ASP associated toxicity, particularly in the presence of predisposing factors.
Conclusions
Combined retrospective observational data from over 11000 patients from four continents suggests that cefazolin is at least as effective as ASPs for SAB, and is associated with less nephrotoxicity. However, given the retrospective design of the available data with the inherent high risk of indication bias, no firm conclusion regarding the pre-specified outcomes can be drawn. Multicentre, randomized controlled studies are required to definitively identify the safest and most effective treatment option for patients with SAB.
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